Notably, a previous study using immunopeptidomics and targeted mass spectrometry demonstrated that there was a lower abundance of KRAS G12V8–16 9-mer peptide per cell compared with the KRAS G12V7–16 10-mer peptide in the context of HLA-A*11:01 on the surface of HLA-A*11:01–engineered natural KRAS G12V+ CORL23 tumor cells (6). Here, KRAS is linked to neoplasm.